Human-derived tumor models are becoming popular in the context of personalized medicine, but a new study shows that these models could be less representative of primary tumors than previously thought, particularly when using late passages.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration
Clinical and Translational Oncology Open Access 29 March 2024
-
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Genome Medicine Open Access 09 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hidalgo, M. et al. Cancer Discov. 4, 998–1013 (2014).
Rubio-Viqueira, B. & Hidalgo, M. Clin. Pharmacol. Ther. 85, 217–221 (2009).
Gao, H. et al. Nat. Med. 21, 1318–1325 (2015).
Ben-David, U. et al. Nat. Genet. 49, 1567–1575 (2017).
Sia, D., Moeini, A., Labgaa, I. & Villanueva, A. Pharmacogenomics 16, 1671–1683 (2015).
Hodgson, J.G. et al. Neuro-oncol. 11, 477–487 (2009).
Aitman, T.J. et al. Nature 439, 851–855 (2006).
Costello, J.C. et al. Nat. Biotechnol. 32, 1202–1212 (2014).
Zitvogel, L., Pitt, J.M., Daillère, R., Smyth, M.J. & Kroemer, G. Nat. Rev. Cancer 16, 759–773 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.V. receives research support from Champions Oncology.
Rights and permissions
About this article
Cite this article
Villacorta-Martin, C., Craig, A. & Villanueva, A. Divergent evolutionary trajectories in transplanted tumor models. Nat Genet 49, 1565–1566 (2017). https://doi.org/10.1038/ng.3983
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3983
This article is cited by
-
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration
Clinical and Translational Oncology (2024)
-
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Genome Medicine (2020)
-
Executable cancer models: successes and challenges
Nature Reviews Cancer (2020)
-
Genomic evolution of cancer models: perils and opportunities
Nature Reviews Cancer (2019)
-
How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective
Journal of Mammary Gland Biology and Neoplasia (2019)